Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa (Q38870646)

7 September 2017

title

Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa (English)

1 reference

Yolande Flore Longang-Tchounkeu

7 September 2017

0 references

object named as

Yolande F L Tchounkeu

1 reference

7 September 2017

Joseph C Okeibunor

1 reference

7 September 2017

Mary Amuyunzu-Nyamongo

1 reference

7 September 2017

Nkechi G Onyeneho

1 reference

7 September 2017

Cele Manianga

1 reference

7 September 2017

Asaph T Kabali

1 reference

7 September 2017

Stephen Leak

1 reference

7 September 2017

publication date

14 March 2011

1 reference

Tropical Medicine and International Health

7 September 2017

published in

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

608-621

1 reference

Community-directed treatment of onchocerciasis with ivermectin in Takum, Nigeria

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

The African Programme for Onchocerciasis Control (APOC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Monitoring community-directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Ivermectin improves the skin condition and self-esteem of females with onchocerciasis: a report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Performance of predictors: evaluating sustainability in community-directed treatment projects of the African programme for onchocerciasis control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Stigma associated with onchocercal skin disease among those affected near the Ofiki and Oyan Rivers in western Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Feasibility of measuring compliance to annual ivermectin treatment in the African Programme for Onchocerciasis Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Gender issues in the community-directed treatment with ivermectin (CDTI) of the African Programme for Onchocerciasis Control (APOC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

African Programme for Onchocerciasis Control (APOC): sociological study in three foci of central Africa before the implementation of treatments with ivermectin (Mectizan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Safety of Sculptra: a review of clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Awareness of the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2000) and compliance to its recommendations: surveys in 2000 and 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

"Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Perceptions on onchocerciasis and ivermectin treatment in rural communities in Uganda: implications for long-term compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Additional health and development activities for community-directed distributors of ivermectin: threat or opportunity for onchocerciasis control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

The rapid monitoring of ivermectin treatment: will school-based surveys provide the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Challenges to early prevention and intervention: personal experiences with adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Appraisal of the knowledge of hypertensive patients and assessment of the role of the pharmacists in the management of hypertension: results of a regional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Research for control: the onchocerciasis experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Historical Origins of the Health Belief Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

The adherence to antiretroviral treatment evaluated from a hospital pharmacy: importance of the protease inhibitors pharmacological class

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Physician contributions to disparities in HIV/AIDS care: the role of provider perceptions regarding adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Impact of ivermectin on illness and disability associated with onchocerciasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Teaching medication compliance to psychiatric residents: placing an orphan topic into a training curriculum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3156.2011.02735.X

10.1111/J.1365-3156.2011.02735.X

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference